INCY

Incyte Corporation | Cotação de Ações

Última atualização31/01/2025, 18:00:01

PreçoUS$ 74,16

Variação (dia)US$ 0,39 (0.53%)▲

Min. 52 SemanasUS$ 50,35

Máx. 52 SemanasUS$ 83,95

Capitalização de mercado--

Endereço: 1801 Augustine Cut-Off, Wilmington, DE, 19803

Telefone: 302 498 6700

Funcionários: 2.524

Incyte CorporationINCY

US$ 74,16

+ 0,390,53%

31/01/2025 18:00:01

1D 7D 1M 3M 1A Tudo

Visão geral da empresa

Preço atualUS$ 74,16

Valor de mercado--

AberturaUS$ 72,60

Preço máximoUS$ 75,17

Preço mínimoUS$ 73,10

VolumeUS$ 1,2 mi

Fechamento anteriorUS$ 73,77

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Ações relacionadas

BioMarin Pharmaceutical Inc.

BMRN ▼0.59% | US$ 61,43

Vertex Pharmaceuticals Incorporated

VRTX ▲1.53% | US$ 429,53

Regeneron Pharmaceuticals, Inc.

REGN ▲4.02% | US$ 684,05

Exelixis, Inc.

EXEL ▼0.14% | US$ 32,74

Alnylam Pharmaceuticals, Inc.

ALNY ▲2.02% | US$ 268,56

Fique por dentro das últimas notícias do mundo financeiro em nosso Blog

Mantenha-se atualizado com as últimas notícias financeiras em nosso Blog. Publicamos artigos informativos e análises de especialistas para fornecer insights valiosos sobre o cenário financeiro em constante evolução.

Assine nossa newsletter para receber atualizações gratuitas por e-mail

Mantenha-se informado assinando nossa newsletter. Receba atualizações gratuitas por e-mail, incluindo rendimentos, novidades do mercado e insights valiosos. Estamos comprometidos em fornecer informações relevantes diretamente à sua caixa de entrada.

Descubra as últimas atualizações do mercado de ações, incluindo os preços de empresas como Magazine Luiza (MGLU3) e Petrobras (PETR4)

Mantenha-se informado sobre o mercado de ações com as atualizações da brapi. Em nossa seção de notícias, fornecemos análises profundas sobre empresas líderes, como Magazine Luiza e Petrobras, auxiliando em decisões de investimento mais esclarecidas.